Lucia Nogová

Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study

Lucia Nogová, Lecia V. Sequist, José Manuel Pérez García et al. · Journal of Clinical Oncology · 2017 · 435 citations · Full text

Medicine, Oncology, Pharmacology +17

K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways

Matthias Scheffler, Michaela A. Ihle, Rebecca Hein et al. · Journal of Thoracic Oncology · 2018 · 259 citations · Full text

Medicine, Genetics, Oncology +17

Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer

Anna Kron, Christina Alidousty, Matthias Scheffler et al. · Annals of Oncology · 2018 · 211 citations · Full text

Medicine, Molecular Genetics, Oncology +17

Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study

Martin Schüler, Byoung Chul Cho, Cyrus Sayehli et al. · The Lancet Oncology · 2019 · 174 citations

Medicine, Oncology, Pharmacology +11

Early Prediction of Nonprogression in Advanced Non–Small-Cell Lung Cancer Treated With Erlotinib By Using [¹⁸F]Fluorodeoxyglucose and [¹⁸F]Fluorothymidine Positron Emission Tomography

Thomas Zander, Matthias Scheffler, Lucia Nogová et al. · Journal of Clinical Oncology · 2011 · 172 citations · Full text

Medicine, Nuclear Medicine, Oncology +17